|
KMID : 1022820100010010006
|
|
Journal of Multiple Sclerosis and Neuroimmunology
2010 Volume.1 No. 1 p.6 ~ p.11
|
|
|
Recent Clinical Trials of Multiple Sclerosis
|
|
An Jae-Young
Lee Kwang-Soo
|
|
|
Abstract
|
|
|
|
The immunopathogenesis of multiple sclerosis has been broadened during the past decade and a number of new strategies were developed for the treatment of the disease. Six pharmacological agents are currently approved for the treatment of multiple sclerosis. However, these drugs are only partially effective and patients may still encounter relapses, disease progression or adverse effects. A sizable number of new agents and optimizing current therapies such as various combination regimens are under investigation currently. However, with availability of newer therapies, the choice of a first-line agent will become more complicated with risk-to-benefit ratios playing a major role in the decision making process.
|
|
|
KEYWORD
|
|
|
Multiple sclerosis, interferon-β, glatiramer acetate, cladribine, fingolimod, monoclonal antibody
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|